
LENZ Stock Forecast & Price Target
LENZ Analyst Ratings
Bulls say
LENZ Therapeutics is expected to have a successful launch of their product VIZZ in the near-term, projected to reach approximately 25,000 paid prescriptions for the first quarter of 2026. Risks to their investment thesis and target price include potential failure to achieve peak commercial revenue estimates and securing necessary funding. A key question is how VIZZ's performance compares to that of AbbVie's VUITY, and how the initial launch trajectory will develop over the coming quarters.
Bears say
LENZ Therapeutics is facing significant challenges in driving sales for its VIZZ product, as it has struggled to gain traction in converting patients to filled prescriptions and building product familiarity and willingness to prescribe among eye care professionals. Despite the company's attempts to expand globally, there is no guarantee of market success in regions such as Europe, the Middle East, Latin America, and Asia. Additionally, the company's valuation and estimated future performance have been adjusted downwards, and there are potential risks to its investment thesis and target price, including failure to achieve peak revenue estimates and secure necessary capital funding.
This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LENZ Analyst Forecast & Price Prediction
Start investing in LENZ
Order type
Buy in
Order amount
Est. shares
0 shares